Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Study data from Cantonal Hospital provide new insights into adverse drug reactions
March 23rd, 2008
"Erlotinib is a small molecule tyrosine kinase inhibitor that is used as an anticancer agent. Most patients develop a pustular facial dermatitis within the first week of treatment," scientists in Geneva, Switzerland report. "Pyogenic granulomas of the nail folds are another typical adverse event occurring in about 10-15% of cases. We report on a patient who developed a generalized dermatitis characterized by neutrophilic spongiosis. Neutrophilic inflammation has been observed in several drugs that interfere with EGFR signaling, suggesting a class effect," wrote J. Lubbe and colleagues, Cantonal Hospital. The researchers concluded: "The present case...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-23)
|
